Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Research Article

Novel Benzoxazin-3-one Derivatives: Design, Synthesis, Molecular Modeling, Anti-HIV-1 and Integrase Inhibitory Assay

Author(s): Mahdieh Safakish, Zahra Hajimahdi, Rouhollah Vahabpour, Rezvan Zabihollahi and Afshin Zarghi*

Volume 16, Issue 7, 2020

Page: [938 - 946] Pages: 9

DOI: 10.2174/1573406415666190826161123

Price: $65

Abstract

Introduction: Integrase is a validated drug target for anti-HIV-1 therapy. The second generation integrase inhibitors display π-stacking interaction ability with 3’-end nucleotide as a streamlined metal chelating pharmacophore.

Methods: In this study, we introduced benzoxazin-3-one scaffold for integrase inhibitory potential as bioisostere replacement strategy of 2-benzoxazolinone.

Results: Molecular modeling studies revealed that amide functionality alongside oxadiazole heteroatoms and sulfur in the second position of oxadiazole ring could mimic the metal chelating pharmacophore. The halobenzyl ring occupies hydrophobic site created by the cytidylate nucleotide (DC-16).

Conclusion: The most potent and selective compound displayed 110 μM IC50 with a selectivity index of more than 2.

Keywords: AIDS, HIV-1, integrase, strand transfer inhibitor, benzoxazin-3-one, docking.

Graphical Abstract
[1]
Kinch, M.S.; Patridge, E. An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. Drug Discov. Today, 2014, 19(10), 1510-1513..
[http://dx.doi.org/10.1016/j.drudis.2014.05.012] [PMID: 2488010]
[2]
Bielenica, A.; Sanna, G.; Madeddu, S.; Struga, M.; Jóźwiak, M.; Kozioł, A.E.; Sawczenko, A.; Materek, I.B.; Serra, A.; Giliberti, G. New thiourea and 1,3-thiazolidin-4-one derivatives effective on the HIV-1 virus. Chem. Biol. Drug Des., 2017, 90(5), 883-891..
[http://dx.doi.org/10.1111/cbdd.13009] [PMID: 28434186]
[3]
Chun, T.W.; Fauci, A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure., AIDS, 2012, 26(10), 1261-1268..
[http://dx.doi.org/10.1097/QAD.0b013e328353f3f1] [PMID: 22472858]
[4]
Mustata, G.I.; Brigo, A.; Briggs, J.M. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(6), 1447-1454..
[http://dx.doi.org//10.1021/jm0600139] [PMID: 16509568]
[5]
Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem., 2006, 49(5), 1506-1508..
[6]
Xue, P.; Lu, H-H.; Zhu, Y-Y.; Ju, X-L.; Pannecouque, C.; Zheng, X-J.; Liu, G-Y.; Zhang, X-L.; Gu, S-X. Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors. Bioorg. Med. Chem. Lett., 2017, 27(8), 1640-1643..
[http://dx.doi.org/10.1016/j.bmcl.2017.03.009] [PMID: 28314598]
[7]
Hightower, K.E.; Wang, R.; Deanda, F.; Johns, B.A.; Weaver, K.; Shen, Y.; Tomberlin, G.H.; Carter, H.L., III; Broderick, T.; Sigethy, S.; Seki, T.; Kobayashi, M.; Underwood, M.R. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitorresistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother., 2011, 55(10), 4552-4559..
[http://dx.doi.org/10.1128/AAC.00157-11] [PMID: 21807982]
[8]
Li, Y.; Xuan, S.; Feng, Y.; Yan, A. Targeting HIV-1 integrase with strand transfer inhibitors. Drug Discov. Today, 2015, 20(4), 435- 449..
[http://dx.doi.org/10.1016/j.drudis.2014.12.001] [PMID: 25486307]
[9]
Hajimahdi, Z.; Zarghi, A. Progress in HIV-1 integrase inhibitors: A review of their chemical structure diversity. Iran. J. Pharm. Res., 2016, 15(4), 595-628.
[PMID: 28243261]
[10]
Velthuisen, E.J.; Johns, B.A.; Temelkoff, D.P.; Brown, K.W.; Danehower, S.C. The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors. Eur. J. Med. Chem., 2016, 117, 99-112.
[http://dx.doi.org/10.1016/j.ejmech.2016.03.038] [PMID: 27092410]
[11]
Hajimahdi, Z.; Ranjbar, A.; Abolfazl Suratgar, A.; Zarghi, A. QSAR Study on Anti-HIV-1 Activity of 4-Oxo-1,4-dihydroquinoline and 4-Oxo-4H-pyrido[1,2-a]pyrimidine derivatives using sw-mlr, artificial neural network and filtering methods. Iran. J. Pharm. Res., 2015, 14(Suppl.), 69-75.
[PMID: 26185507]
[12]
Raheem, I.T.; Walji, A.M.; Klein, D.; Sanders, J.M.; Powell, D.A.; Abeywickrema, P.; Barbe, G.; Bennet, A.; Childers, K.; Christensen, M.; Clas, S.D.; Dubost, D.; Embrey, M.; Grobler, J.; Hafey, M.J.; Hartingh, T.J.; Hazuda, D.J.; Kuethe, J.T.; McCabe Dunn, J.; Miller, M.D.; Moore, K.P.; Nolting, A.; Pajkovic, N.; Patel, S.; Peng, Z.; Rada, V.; Rearden, P.; Schreier, J.D.; Sisko, J.; Steele, T.G.; Truchon, J.F.; Wai, J.; Xu, M.; Coleman, P.J. Discovery of 2- pyridinone aminals: a prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors. J. Med. Chem., 2015, 58(20), 8154-8165..
[http://dx.doi.org/10.1021/acs.jmedchem.5b01037] [PMID: 26397965]
[13]
DeAnda, F.; Hightower, K.E.; Nolte, R.T.; Hattori, K.; Yoshinaga, T.; Kawasuji, T.; Underwood, M.R. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One, 2013, 8(10), e77448..
[http://dx.doi.org/10.1371/journal.pone.0077448] [PMID: 24146996]
[14]
Schreier, J.D.; Embrey, M.W.; Raheem, I.T.; Barbe, G.; Campeau, L-C.; Dubost, D.; McCabe Dunn, J.; Grobler, J.; Hartingh, T.J.; Hazuda, D.J.; Klein, D.; Miller, M.D.; Moore, K.P.; Nguyen, N.; Pajkovic, N.; Powell, D.A.; Rada, V.; Sanders, J.M.; Sisko, J.; Steele, T.G.; Wai, J.; Walji, A.; Xu, M.; Coleman, P.J. Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV. Bioorg. Med. Chem. Lett., 2017, 27(9), 2038-2046..
[http://dx.doi.org/10.1016/j.bmcl.2017.02.039] [PMID: 28285916]
[15]
Honda, T.; Terao, T.; Aono, H.; Ban, M. Synthesis of novel 1,4- benzoxazin-3-one derivatives as inhibitors against tyrosine kinases. Bioorg. Med. Chem., 2009, 17(2), 699-708..
[http://dx.doi.org/10.1016/j.bmc.2008.11.060] [PMID: 19109024]
[16]
Alper-Hayta, S.; Aki-Sener, E.; Tekiner-Gulbas, B.; Yildiz, I.; Temiz-Arpaci, O.; Yalcin, I.; Altanlar, N. Synthesis, antimicrobial activity and QSARs of new benzoxazine-3-ones. Eur. J. Med.Chem., 2006, 41(12), 1398-1404.,
[http://dx.doi.org/0.1016/j.ejmech.2006.06.011] [PMID: 16996656]
[17]
Anderluh, M.; Cesar, J.; Štefanič, P.; Kikelj, D.; Janeš, D.; Murn, J.; Nadrah, K.; Tominc, M.; Addicks, E.; Giannis, A. Synthesis, antimicrobial activity and QSARs of new benzoxazine-3-ones. Eur. J. Med. Chem., 2005, 40, 25-49.,
[http://dx.doi.org/10.1016/j.ejmech.2004.09.004] [PMID: 15642407]
[18]
Savelon, L.; Bizot-Espiard, J.G.; Caignard, D.H.; Pfeiffer, B.; Renard, P.; Viaud, M.C.; Guillaumet, G. Substituted pyrido[3,2- b]oxazin-3(4H)-ones: synthesis and evaluation of antinociceptive activity. Bioorg. Med. Chem., 1998, 6(2), 133-142..
[http://dx.doi.org/10.1016/S0968-0896(97)10005-0] [PMID: 9547936]
[19]
Poupaert, J.; Carato, P.; Colacino, E.; Yous, S. 2(3H)- benzoxazolone and bioisosters as “privileged scaffold” in the design of pharmacological probes. Curr. Med. Chem., 2005, 12(7), 877- 885..
[http://dx.doi.org/10.2174/0929867053507388] [PMID: 15853716]
[20]
Safakish, M.; Hajimahdi, Z.; Zabihollahi, R.; Aghasadeghi, M.R.; Vahabpour, R.; Zarghi, A. Design, synthesis, and docking studies of new 2-benzoxazolinone derivatives as anti-HIV-1 agents. Med. Chem. Res., 2017, 26, 2718-2726..
[http://dx.doi.org/10.1007/s00044-017-1969-8]
[21]
Caliendo, G.; Grieco, P.; Perissutti, E.; Santagada, V.; Santini, A.; Albrizio, S.; Fattorusso, C.; Pinto, A.; Sorrentino, R. Synthesis, biological activity and conformational study of 1,4-benzoxazine derivatives as potassium channel modulators. Eur. J. Med. Chem., 1998, 33, 957-967.946 Medicinal Chemistry, 2020, Vol. 16, No. 7 Safakish et al..
[http://dx.doi.org/10.1016/S0223-5234(99)80020-8]
[22]
Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem., 2008, 8(18), 1555-1572..
[http://dx.doi.org/10.2174/156802608786786624] [PMID: 19075767]
[23]
Zabihollahi, R.; Sadat, S.M.; Vahabpour, R.; Aghasadeghi, M.R.; Memarnejadian, A.; Ghazanfari, T.; Salehi, M.; Rezaei, A.; Azadmanesh, K. Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virol., 2011, 55(1), 15-22.,
[http://dx.doi.org/10.4149/av_2011_01_15] [PMID: 21434701]
[24]
Lin, C.C.; Cheng, H.Y.; Yang, C.M.; Lin, T.C. Antioxidant and antiviral activities of Euphorbia thymifolia L. J. Biomed. Sci., 2002, 9(6 Pt 2), 656-664..
[http://dx.doi.org/10.1159/000067281] [PMID: 12432232]
[25]
Scudiero, D.A.; Shoemaker, R.H.; Paull, K.D.; Monks, A.; Tierney, S.; Nofziger, T.H.; Currens, M.J.; Seniff, D.; Boyd, M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 1988, 48(17), 4827-4833.
[PMID: 3409223]
[26]
Sala, M.; Spensiero, A.; Esposito, F.; Scala, M.C.; Vernieri, E.; Bertamino, A.; Manfra, M.; Carotenuto, A.; Grieco, P.; Novellino, E.; Cadeddu, M.; Tramontano, E.; Schols, D.; Campiglia, P.; Gomez-Monterrey, I.M. Development and identification of a novel anti-HIV-1 peptide derived by modification of the n-terminal domain of HIV-1 integrase. Front. Microbiol., 2016, 7, 845..
[http://dx.doi.org/10.3389/fmicb.2016.00845] [PMID: 27375570]
[27]
Combs, D.W.; Rampulla, M.S.; Bell, S.C.; Klaubert, D.H.; Tobia, A.J.; Falotico, R.; Haertlein, B.; Lakas-Weiss, C.; Moore, J.B. 6- Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem., 1990, 33(1), 380-386..
[http://dx.doi.org/10.1021/jm00163a061] [PMID: 2153210]
[28]
Zarghi, A.; Hamedi, S.; Tootooni, F.; Amini, B.; Sharifi, B.; Faizi, M.; Tabatabai, S.; Shafiee, A. Synthesis and Pharmacological Evaluation of New 2-Substituted-5-2-[(2-halobenzyl)thio)phenyl- 1,3,4-oxadiazoles as Anticonvulsant Agents. Sci. Pharm., 2008, 76, 185-201..
[http://dx.doi.org/10.3797/scipharm.0803-10]
[29]
Zarghi, A.; Hajimahdi, Z.; Mohebbi, S.; Rashidi, H.; Mozaffari, S.; Sarraf, S.; Faizi, M.; Tabatabaee, S.A.; Shafiee, A. Design and synthesis of new 2-substituted-5-[2-(2-halobenzyloxy)phenyl]-1,3,4- oxadiazoles as anticonvulsant agents. Chem. Pharm. Bull. (Tokyo), 2008, 56(4), 509-512..
[http://dx.doi.org/10.1248/cpb.56.509] [PMID: 18379099]
[30]
Zarghi, A.; Hajimahdi, Z. Substituted oxadiazoles: a patent review (2010-2012). Expert Opin. Ther. Pat., 2013, 23, 1209-1232.
[31]
Hajimahdi, Z.; Zabihollahi, R.; Aghasadeghi, M.R.; Zarghi, A. Design, synthesis and docking studies of new 4-hydroxyquinoline- 3-carbohydrazide derivatives as anti-HIV-1 agents. Drug Res. (Stuttg.), 2013, 63(4), 192-197..
[http://dx.doi.org/10.1055/s-0033-1334964] [PMID: 23487403]
[32]
Hajimahdi, Z.; Zarghi, A.; Zabihollahi, R.; Aghasadeghi, M.R. Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4Hpyrido[1,2-a]pyrimidines as anti-HIV-1 agents. Med. Chem. Res., 2013, 22, 2467-2475..
[http://dx.doi.org/10.1007/s00044-012-0241-5]
[33]
Hajimahdi, Z.; Zabihollahi, R.; Aghasadeghi, M.R.; Ashtiani, S.H.; Zarghi, A. Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities., Med. Chem. Res., 2016, 25, 1861-1876..
[http://dx.doi.org/10.1007/s00044-016-1631-x]
[34]
Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer., Nature, 2010, 464(7286), 232-236..
[http://dx.doi.org/10.1038/nature08784] [PMID: 20118915]
[35]
Billamboz, M.; Bailly, F.; Lion, C.; Calmels, C.; Andréola, M-L.; Witvrouw, M.; Christ, F.; Debyser, Z.; De Luca, L.; Chimirri, A.; Cotelle, P. 2-hydroxyisoquinoline-1,3(2H,4H)-diones as inhibitors of HIV-1 integrase and reverse transcriptase RNase H domain: influence of the alkylation of position 4. Eur. J. Med. Chem., 2011, 46(2), 535-546..
[http://dx.doi.org/10.1016/j.ejmech.2010.11.033] [PMID: 21185110]
[36]
Roviello, G.N.; Musumeci, D.; Moccia, M.; Castiglione, M.; Sapio, R.; Valente, M.; Bucci, E.M.; Perretta, G.; Pedone, C. dabPNA: design, synthesis, and DNA binding studies. Nucleosides Nucleotides Nucleic Acids, 2007, 26(10-12), 1307-1310..
[http://dx.doi.org/10.1080/15257770701530640] [PMID: 1806677]
[37]
Roviello, G.N.; Musumeci, D.; Roviello, V.; Pirtskhalava, M.; Egoyan, A.; Mirtskhulava, M. Natural and artificial binders of polyriboadenylic acid and their effect on RNA structure. Beilstein J. Nanotechnol., 2015, 6, 1338-1347.,
[http://dx.doi.org/10.3762/bjnano.6.138] [PMID: 26199837]
[38]
Roviello, G.N.; Vicidomini, C.; Di Gaetano, S.; Capasso, D.; Musumeci, D.; Roviello, V. Solid phase synthesis and RNAbinding activity of an arginine-containing nucleopeptide. RSC Advan., 2016, 6(17), 14140-14148..
[http://dx.doi.org/10.1039/C5RA25809J] [PMID: 29057071]
[39]
Roviello, G.N.; Di Gaetano, S.; Capasso, D.; Cesarani, A.; Bucci, E.M.; Pedone, C. Synthesis, spectroscopic studies and biological activity of a novel nucleopeptide with Moloney murine leukemia virus reverse transcriptase inhibitory activity. Amino Acids, 2010, 38(5), 1489-1496..
[http://dx.doi.org//10.1007/s00726-009-0361-5] [PMID: 19813074]
[40]
Vicidomini, C.; Cioffi, F.; Broersen, K.; Roviello, V.; Riccardi, C.; Montesarchio, D.; Capasso, D.; Gaetano, S.D.; Musumeci, D.; Roviello, G.N. Benzodifurans for biomedical applications: BZ4, a selective anti-proliferative and anti-amyloid lead compound. Future Med. Chem., 2019, Epub ahead of print.
[http://dx.doi.org/10.4155/fmc-2018-0473] [PMID: 30801198]
[41]
Carella, A.; Roviello, V.; Iannitti, R.; Palumbo, R.; La Manna, S.; Marasco, D.; Trifuoggi, M.; Diana, R.; Roviello, G.N. Evaluating the biological properties of synthetic 4-nitrophenyl functionalized benzofuran derivatives with telomeric DNA binding and antiproliferative activities. Int. J. Biol. Macromol., 2019, 121, 77-88..
[http://dx.doi.org/10.1016/j.ijbiomac.2018.09.153] [PMID: 30261256]
[42]
Roviello, G.N. Novel insights into nucleoamino acids: biomolecular recognition and aggregation studies of a thymine-conjugated Lphenyl alanine. Amino Acids, 2018, 50(7), 933-941..
[http://dx.doi.org/10.1007/s00726-018-2562-2] [PMID: 29766280]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy